MannKind reported $134.56M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Adma Biologics USD 73.54M 4M Mar/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Insmed USD 361.01M 107.87M Mar/2026
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
MacroGenics USD 95.94M 52.82M Mar/2026
MannKind USD 134.56M 36.47M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Novavax USD 342.46M 117.49M Mar/2026
Novo Nordisk DKK 32.79B 203.33B Jun/2025
Pfizer USD 34.35B 2.64B Mar/2026
Sanofi EUR 30.01B 1.66B Mar/2026
Xencor USD 73.46M 22.45M Mar/2026